Navigating the New EU Pharma Package, Part 2

Launch, supply, evidence: Europe raises the bar.

Cover of the white paper Navigating the New EU Pharma Package, Part 2

Part 2 of our deep dive into the New EU Pharma Package.

Part 1 covered incentives, orphans, paediatrics and EMA pathways. Part 2 examines what the reform changes for access and supply obligations, platform regulation, environmental requirements, digitalisation and regulatory evidence, and how the proposed European Biotech Act complements it.

This White Paper uncovers:

  • How a Member State launch request can cost you regulatory protection locally under Art. 59.
  • The new 12- and 6-month notification deadlines for withdrawals, suspensions and supply disruptions.
  • How the PTMF and the platform MA differ, illustrated with AAV and mRNA examples.
  • Why an incomplete ERA may now lead to MA refusal, and what changes for electronic package leaflets.
  • What the European Biotech Act would add, from financing to a 12-month SPC extension.

Access our White Paper